MYBL2 and uterine corpus endometrial carcinoma: This study employed integrated bioinformatics analysis combined with clinical sample validation to assess MYBL2 as a prognostic biomarker for uterine corpus endometrial carcinoma (UCEC) and to elucidate its associations with methylation modification, immune infiltration patterns, and sensitivity to antitumor drugs.